ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Cancer Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1666699
This article is part of the Research TopicUnveiling the Complexity of Neuroendocrine Neoplasms: Biomarkers, Classification, and Translational PerspectivesView all articles
MANAGEMENT OF TYPE I GASTRIC-NEUROENDOCRINE TUMORS: THE LESS THE BETTER?
Provisionally accepted
Roberta Elisa Rossi*
Benedetta Masoni
Valeria PolettiRoberta MaselliSilvia CarraraAlexia Francesca Bertuzzi
Silvia UccellaAndrea LaniaAlessandro ZerbiCesare HassanAlessandro Repici- Humanitas Research Hospital, Rozzano, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background and aims: Type I gastric neuroendocrine tumors (gNETs) are known for their favorable prognosis. We aimed to present a real-life experience at a ter`ary referral center.Retrospec`ve analysis of pa`ents diagnosed with type I gNETs at our Ins`tu`on between 2014-2024.Results: 36 lesions were iden`fied in 23 pa`ents, median tumor size 7 mm (range 2-20 mm). 29/36 lesions were G1, 7 G2. In 13 cases endoscopic ultrasound (EUS) was performed prior to resec`on, revealing lymph node involvement in one 20 mm G1 lesion that required surgery. A 15 mm G2 lesion underwent surgery. In the remaining 34 lesions, endoscopic resec`on was performed: forceps in 5, cold-snare polypectomy in 4, hot-EMR in 22, EMR-cap in 1, ESD in 1, hybrid-ESD in 1. Amongst those, one 5 mm G2 lesion, previously removed via simple polypectomy, required surgery due to 14.5% Ki-67 index. The median follow-up was 14 months (range 1-120), with 10 cases of local recurrence in 6 pa`ents, median tumor size 3 mm (range 2-8 mm), all G1. In 3 cases endoscopic surveillance was indicated; 7 NETs underwent endoscopic resec`on (3 forceps, 2 EMRcap, 2 EMR), being EUS performed in 4 cases with nega`ve results. No local/distant metastases occurred nor tumor-related deaths.Conclusions: Present data confirm an indolent behavior for type I gNETs. Pre-opera`ve EUS staging led to a change in the management in one case, which highlights the need of dedicated studies to iden`fy predic`ve factors to stra`fy risk and plan the management of these neoplasms.
Keywords: gastric neuroendocrine tumors, gastric carcinoids, autoimmune chronic atrophic gastri`s, endoscopic resec`on, Recurrence, Survival
Received: 15 Jul 2025; Accepted: 08 Aug 2025.
Copyright: © 2025 Rossi, Masoni, Poletti, Maselli, Carrara, Bertuzzi, Uccella, Lania, Zerbi, Hassan and Repici. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Roberta Elisa Rossi, Humanitas Research Hospital, Rozzano, Italy
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.